Title:
CRYSTAL FORM OF QUINAZOLINONE COMPOUND AND PREPARATION METHOD THEREFOR
Document Type and Number:
WIPO Patent Application WO/2020/228729
Kind Code:
A1
Abstract:
The present invention relates to a crystal form of a compound of formula (I), which acts as a PI3Kα inhibitor, and a preparation method therefor, and the use thereof in the preparation of a medicine for treating solid tumors.
More Like This:
| JP2009518364 | Pyrimidil that suppresses growth, condensed pyrimidil, pyridyl hydrazone |
| WO/2001/087855 | TRIAZOLE DERIVATIVES |
| JP2001233767 | APO AI EXPRESSION STHENIC AGENT |
Inventors:
HUANG JINGJIE (CN)
YIN YIJIE (CN)
YAO TING (CN)
YU TAO (CN)
WU CHENGDE (CN)
DONG JIAQIANG (CN)
SHI BIN (CN)
TANG WEI (CN)
YANG WENQIAN (CN)
WANG TIE-LIN (CN)
YIN YIJIE (CN)
YAO TING (CN)
YU TAO (CN)
WU CHENGDE (CN)
DONG JIAQIANG (CN)
SHI BIN (CN)
TANG WEI (CN)
YANG WENQIAN (CN)
WANG TIE-LIN (CN)
Application Number:
PCT/CN2020/089972
Publication Date:
November 19, 2020
Filing Date:
May 13, 2020
Export Citation:
Assignee:
LUOXIN PHARMACEUTICAL SHANGHAI CO LTD (CN)
SHANDONG LUOXIN PHARMACY STOCK (CN)
SHANDONG LUOXIN PHARMACY STOCK (CN)
International Classes:
C07D401/04; A61K31/517; A61P35/00
Domestic Patent References:
| WO2019091476A1 | 2019-05-16 | |||
| WO2010029082A1 | 2010-03-18 |
Foreign References:
| CN108239067A | 2018-07-03 | |||
| CN201910394653A | 2019-05-13 | |||
| CN201910423711A | 2019-05-21 |
Other References:
See also references of EP 3971175A4
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: